[A derivative of quinolone Semaxanib blocks ATP binding to the tyrosine kinase domain of vascular endothelial growth factor receptor 2 (VEGFR2), thereby inhibiting VEGF-stimulated endothelial cell migration and proliferation and decreasing the density of microvessels supplying tumors. This agent also inhibits the phosphorylation of the stem cell factor receptor tyrosine kinase c-kit, often expressed in acute myelogenous leukemia cells. Semaxanib has been studied for potential antineoplastic properties. (NCI04) ( NCI )]
UMLS (NCI) C1135174 - Organic Chemical
- Pharmacologic Substance